<DOC>
	<DOCNO>NCT00037544</DOCNO>
	<brief_summary>To characterize safety efficacy ReFacto AF treat acute bleed episode prophylaxis treatment , include neoantigenicity .</brief_summary>
	<brief_title>Study Evaluating ReFacto AF Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( FVIII : C le equal 2 % local laboratory ) Previously treat patient great equal 250 exposure day Factor VIII product Age great equal 12 year History prophylaxis dose least twice per week Factor VIII product least 3 consecutive month within 2 year prior study enrollment unless patient complete previous pharmacokinetic study Adequate laboratory result Presence bleed disorder addition hemophilia A Concomitant therapy immunosuppressive drug Current historical Factor VIII inhibitor Treatment investigational drug device within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Severe</keyword>
	<keyword>Hemophilia</keyword>
	<keyword>A</keyword>
</DOC>